Korean regulators shut down Samsung Pharma manufacturing after finding additives, false records
South Korea’s health regulator has suspended Samsung Pharmaceutical’s manufacturing operations until mid-February after the agency learned that a production manager was tasked with responsibilities of two different plants. The revelation violated a law requiring each plant to be managed by one person.
Monday’s halt comes just months after an inspection revealed a number of violations at one Samsung Pharma plant, including the use of additives without permission and false manufacturing records, the Korea Biomedical Review reported.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.